ArticleFrontiers in oncology2025
Analysis of the safety and efficacy of microwave ablation of several foci of multiple lung metastases from colorectal cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to retrospectively analyze the safety and effectiveness of microwave ablation (MWA) in treating multiple lung metastases from colorectal cancer. Additionally, it seeks to compare the superiority of single multiple ablation and fractionated multiple ablation for unilateral lung multiple metastases. Materials and methods: Retrospective analysis was conducted on clinical and pathological data of 82 patients with such multiple lung metastases from colorectal cancer treated from January 2020 to December 2022. Patients were categorized based on the number of MWA sessions required,Patients who had received only one MWA treatment were included in the single MWA group, and patients who had received two or more MWA treatments were included in the multiple MWA group. Chest-enhanced CT scans were performed at 1, 3, 6, and 12 months post-MWA to assess ablation outcomes. The primary focus was the median overall survival (mOS), while secondary endpoints encompassed median progression-free survival (mPFS), technical success rates, and safety. Analysis was performed by log-rank test and Cox proportional hazard regression model, using the Common Terminology Standard for Adverse Events (version 5.0) to assess safety within 28 days after MWA. Results: There were 82 patients with numerous lung metastases from colorectal cancer, and they had a total of 182 lesions. These patients underwent 112 microwave ablation (MWA) treatments. Each patient received at least two MWA treatments for their target lesions. The overall median overall survival (mOS) time for all patients was 25 months, the median progression-free survival (mPFS) time was 21 months. No deaths or severe adverse events occurred as a result of the treatment. The univariate Cox regression analysis indicated that fractional MWA ( Conclusion: Microwave ablation proves to be a safe and efficacious treatment modality for colorectal cancer-associated multiple pulmonary metastases, offering substantial clinical benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.